Analyst firms · Leerink Partners · ADAP

Leerink Partners ADAP price target and rating history

Adaptimmune Therapeutics plc (ADAP) · Health Care

Leerink Partners rates Adaptimmune Therapeutics plc (ADAP) Market Perform with a $7 price target, as of its latest action on Sep 13, 2021. It has published 3 rating actions on ADAP since August 2021, including 0 upgrades and 0 downgrades.

Current rating
Market Perform
Price target
$7
Median target, all firms
Too few
Actions on ADAP
3

Leerink Partners price target on ADAP

$7$6$520222023202420252026
Leerink Partners price target on ADAP, each point a stated target, August 2021 to September 2021.

Every Leerink Partners rating on ADAP

Questions about Leerink Partners and ADAP

What is Leerink Partners's price target for ADAP?
Leerink Partners's latest stated price target for Adaptimmune Therapeutics plc (ADAP) is $7, from its action on Sep 13, 2021.
What is Leerink Partners's rating on ADAP?
Leerink Partners rates ADAP Market Perform, a neutral rating, as of Sep 13, 2021.
When did Leerink Partners last change its view on ADAP?
On Sep 13, 2021, Leerink Partners raises its price target to $7 from $6, keeps Market Perform.

All Leerink Partners ratingsADAP news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.